Asthma

March 2018 | by EMauthor


Generalised narrowing of the airways which varies over short periods of time either spontaneously or as a result of treatment


•Moderate Asthma

oClinical features:

■No features of acute severe asthma

■Increasing symptoms

oMeasurements:

■PEF > 50–75 % of best or predicted

•Severe Asthma

oClinical features:

■Inability to complete sentences in one breath

oMeasurements:

■PEF 33–50 % of best or predicted

■Respiratory Rate ≥ 25 breaths per minute

■Heart Rate ≥ 110 beats per minute

•Life-threatening

oClinical features:

■Silent chest

■Cyanosis

■Feeble respiratory effort

■Arrhythmia, hypotension

■Exhaustion, altered conscious level

oMeasurements:

■PEF <33 % of best or predicted

■SpO 2 <92 %

■PaO2 < 8 kPa

■Normal PaCO2 (4.6–6.0)

•Near fatal

oRaised PaCO2 and/or requiring positive pressure ventilation with raised inflation pressures


Investigations in Asthma


•Peak expiratory fl ow rate; should be measured in all acute presentations. It should be expressed as a percentage of the patient’s previous best value or predicted best.

•Arterial blood gas; is recommended by BTS if SpO2 <92% or other features of lifethreatening asthma are present.

•Chest radiographs are not routinely recommended. They should be performed if a pneumothorax, pneumomediastinum, or consolidation is suspected; in life-threatening asthma; if there is failure to respond to treatment; or if mechanical ventilation is required.


Treatment in ED


•Oxygen to maintain saturations between 94–98 %

•Salbutamol. In moderate and severe asthma via a metered-dose inhaler with a large spacer. In asthma with life-threatening features, the nebulized route (oxygen driven) is recommended (e.g. salbutamol 5 mg).

oIn patients with a poor response to initial β2 agonist therapy, it can be nebulized continuously.

oIntravenous β 2 agonists should be reserved for those patients in whom inhaled therapy cannot be used reliably.

•Nebulized Ipratropium bromide (500 mcg) should be added to β 2 agonist therapy in severe and life threatening asthma or in those with a poor initial response to β 2 agonist. It can be repeated every 4–6 hours.

•Prednisolone is 40–50 mg for at least 5 days

•The dose of intravenous hydrocortisone is 100 mg

•Magnesium sulphate is a bronchodilator. It should be given in life-threatening and near fatal asthma, and in those with severe asthma who have had a poor response to inhaled therapy.

oMagnesium can be nebulized or given intravenously. 2 g over 20 minutes.

•Consider aminophylline


Discharge criteria for acute asthma


Patients whose PEF is greater than 75 % best or predicted 1 hour after initial treatment may be

discharged from the ED. Patients should be discharged with:


•Oral prednisolone 40–50 mg for 5 days and inhaled steroids (e.g. beclomethasone inhaler).

•Sufficient and in-date inhaled bronchodilator (e.g. salbutamol).

•PEF meter.

•Written asthma plan.

•GP follow up arranged for within 2 days.


Links

•HOSPITAL ADMISSION

•HOME

•INTRANET HUB





Created with the Personal Edition of HelpNDoc: Easily create iPhone documentation